These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 32274571)
1. High incidence of antiresorptive agent-related osteonecrosis of the jaw in patients with rheumatoid arthritis. Watanabe R J Bone Miner Metab; 2020 Sep; 38(5):737-738. PubMed ID: 32274571 [No Abstract] [Full Text] [Related]
2. Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis. Fujieda Y; Atsumi T J Bone Miner Metab; 2020 Sep; 38(5):739-741. PubMed ID: 32591907 [No Abstract] [Full Text] [Related]
3. Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease. Fujieda Y; Doi M; Asaka T; Ota M; Hisada R; Ohnishi N; Kono M; Kameda H; Nakazawa D; Kato M; Amengual O; Takahata M; Yasuda S; Kitagawa Y; Atsumi T J Bone Miner Metab; 2020 Jul; 38(4):581-588. PubMed ID: 32076874 [TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I. Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591 [TBL] [Abstract][Full Text] [Related]
5. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. Dodson TB Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367 [TBL] [Abstract][Full Text] [Related]
6. The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw. Fantasia JE Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):547-53. PubMed ID: 26515736 [TBL] [Abstract][Full Text] [Related]
7. Development of Antiresorptive Agent-Related Osteonecrosis of the Jaw After Dental Implant Removal: A Case Report. Yamamoto S; Maeda K; Kouchi I; Hirai Y; Taniike N; Yamashita D; Imai Y; Takenobu T J Oral Implantol; 2018 Oct; 44(5):359-364. PubMed ID: 29870295 [TBL] [Abstract][Full Text] [Related]
8. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan. Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558 [TBL] [Abstract][Full Text] [Related]
9. Drug induced osteonecrosis of the jaw. Hamadeh IS; Ngwa BA; Gong Y Cancer Treat Rev; 2015 May; 41(5):455-64. PubMed ID: 25913713 [TBL] [Abstract][Full Text] [Related]
10. Tooth extractions in patients under antiresorptive therapy for osteoporosis: Primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. Poxleitner P; Steybe D; Kroneberg P; Ermer MA; Yalcin-Ülker GM; Schmelzeisen R; Voss PJ J Craniomaxillofac Surg; 2020 Apr; 48(4):444-451. PubMed ID: 32122726 [TBL] [Abstract][Full Text] [Related]
11. Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw. Mathai PC; Andrade NN; Aggarwal N; Nerurkar S; Kapoor P Oral Maxillofac Surg; 2018 Jun; 22(2):235-240. PubMed ID: 29508096 [TBL] [Abstract][Full Text] [Related]
12. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668 [TBL] [Abstract][Full Text] [Related]
13. Lenvatinib and osteonecrosis of the jaw: A pharmacovigilance study. Lu W; Guo Q; Ma Z; Liu L; Zhao Z Eur J Cancer; 2021 Jun; 150():211-213. PubMed ID: 33934057 [No Abstract] [Full Text] [Related]
14. United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis. Rogers SN; Palmer NO; Lowe D; Randall C Br J Oral Maxillofac Surg; 2015 Feb; 53(2):176-82. PubMed ID: 25497376 [TBL] [Abstract][Full Text] [Related]
15. Antiresorptive drug-related osteonecrosis of the jaw. Uyanne J; Calhoun CC; Le AD Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528 [TBL] [Abstract][Full Text] [Related]
16. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Yamazaki T; Yamori M; Ishizaki T; Asai K; Goto K; Takahashi K; Nakayama T; Bessho K Int J Oral Maxillofac Surg; 2012 Nov; 41(11):1397-403. PubMed ID: 22840716 [TBL] [Abstract][Full Text] [Related]
17. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs. Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661 [TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the jaws. Toole J Rheumatology (Oxford); 2015 Oct; 54(10):1755-6. PubMed ID: 25877909 [No Abstract] [Full Text] [Related]
19. Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sjögren's syndrome: nationwide population-based cohort study. Liao MT; Chien WC; Wang JC; Chung CH; Chu SJ; Tsai SH BMJ Open; 2019 Feb; 9(2):e024655. PubMed ID: 30765404 [TBL] [Abstract][Full Text] [Related]